Sidra undertakes four pioneering heart surgeries
31 May 2017 - 1:49
Prof Ziyad M Hijazi, Chair of the Department of Paediatrics and the Director of the Sidra Cardiac Program at Sidra Medical and Research Center (Sidra) recently performed and oversaw four pioneering surgeries on congenital heart defects (CHD) patients in Qatar, with a new proprietary heart valve.
Prof Hijazi is an interventional cardiologist who is a pioneer and specialist in treating congenital and structural heart disease in both children and adults. His major area of interest is in the development of techniques, catheters, devices and valves to help treat or cure congenital and structural cardiac disease without open-heart surgery.
In his ongoing mission to implement minimally invasive procedures for CHD patients and to drive forward Sidra’s clinical research agenda, Prof Hijazi has been the Global Principal Investigator (PI) for a consortium of international cardiac interventionists to evaluate a new heart valve – the Venus P-valve. The valve, manufactured by Venus Medtech (Hangzhou) Inc is seeking to address the needs of a large majority of CHD patients who are unable to benefit from existing minimally-invasive valve implantations and have to undergo open-heart surgery.
Prof Hijazi, the Global PI and expert in implanting the Venus P-Valve, said, “Clinical research is a key part of our remit at Sidra. As surgeons and physicians we are committed to ensuring that we never stop researching new treatment and technologies that can save lives and ease the care and treatment of our patients.”
“The Venus P-valve implantations were a truly pioneering procedure for CHD patients in Qatar. This is the first time that the implantation with the valve has been done in the country after successful evaluations in other parts of the world. More than 100 patients worldwide have benefited from the implantation. Thanks to the foresight and vision to support advancement in healthcare, the Ministry of Public Health in Qatar granted Sidra the rights to bring this innovation to Qatar,” Prof Hijazi added.
The trans-catheter self-expanding Venus P-Valve, designed for the pulmonary valve, is implanted via a catheter inserted through the groin. The process does not require the use of a heart and lung machine to stop the heart during the operation (normally done during open-heart surgery). The procedure is carried out while the heart is still beating.
The Qatar-based patients, ranging from ages 14 to 40, received the Venus P-Valve implantations at Hamad General Hospital. The operations were performed jointly by Prof Hijazi and Dr Qi-Ling Cao from Sidra and Dr Hesham Al Saloos, an interventional cardiologist from Hamad Medical Corporation.